Product Name: NDR1 (277-291) pS281+pT282+pT285+pY288
Product Number: PE-04AWR85
| Size: | 200 µg | Price: | 81.00 | |
| 1 mg | $US | 162.00 |
Peptide Name: NDR1 (277-291) pS281+pT282+pT285+pY288
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S281 phosphorylation stimulates phosphotransferase activity. T282 phosphorylation is predicted to be stimulatory for phosphotransferase activity, whereas T285 and Y288 are predicted to be inhibitory.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: QLAF-pS-TVG-pT-PD-pY-IAP
Peptide Modifications N Terminus: Free amino
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S281 phosphorylation stimulates phosphotransferase activity. T282 phosphorylation is predicted to be stimulatory for phosphotransferase activity, whereas T285 and Y288 are predicted to be inhibitory.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: QLAF-pS-TVG-pT-PD-pY-IAP
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 2035.1 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 2035.1 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Scientific Background: NDR1 (STK38) is a protein-serine/threonine kinase of the AGC group and NDR family. It is activated by binding of S100B, which releases autoinhibitory N-lobe interactions, enabling ATP to bind and the autophosphorylation of S281. Phosphorylation at S281 increases phosphotransferase activity and interaction with MOBP. T444 then undergoes calcium-dependent phosphorylation by an upstream kinase. Interactions between phosphorylated T444 and the N-lobe promote additional structural changes that complete the activation of the kinase. Phosphorylation at T74 induces interaction with S100B. T444 then undergoes calcium-dependent phosphorylation by an upstream kinase. T74A, K118A, S281A, and T444A mutations are involved in decreased or loss of autophosphorylation and kinase activity. NDR1 is a negative regulator of MAP3K1/2 signalling. It converts MAP3K2 from its phosphorylated form to its nonphosphorylated form and inhibits autophosphorylation of MAP3K2. NDR1 is an important regulator of Myc's oncogenic activity in human B-cell lymphomas. It also regulates G/S cell cycle transition. The MAPK/ERK pathway has been implicated in oncogenesis as either a promoter or inhibitor depending on the cancer system.
© Kinexus Bioinformatics Corporation 2017